Flatlander schreef op 22 oktober 2019 01:02:
I would love it if DRZ would back up his strong anti BCART stance with facts. Lets face it, his negative sentiment has been correct thus far this year. However, I'd like to know why he or anyone else would remain negative after the 40% haircut when the problems in the US (that caused the drop) are by no means permanent.
As I mentioned before, I was blocked from purchasing additional shares on the Schwab Global Platform. I opened a Interactive Brokers account so I could add shares after the midyear report drop in share price. At this point looking forward I can see numerous potential catalysts occurring in the next year including:
Septicyte Registration in EU and US;
Onco DX Breast validation announcement and timing of EU roll out starting in Germany and France;
Wonfu China Registration/Launch information;
Nichirei Bioscience Registration/Launch in Japan;
US FDA MSI 510 Approval;
Update on Onco DX Prostate Urology proof of concept;
New Partnership announcements; and
Demonstration of Sales traction in the US and Rest of World.
Several of these catalysts can be expected to result in significantly increased sales and improved financial metrics. I think 2020 will be a transitional year for BCART. Based on the catalysts I've identified, I believe profitability will be achieved in 2021. Geographical expansion will require significant continued investment but it is important that BCART press their first mover advantage.